Sumie Koike

Japanese Foundation For Cancer Research — Japan

Medicine · Health Sciences

15h-index1.6kcitations37works2.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(20), Cancer therapeutics and mechanisms(11), Colorectal Cancer Treatments and Studies(5), Lung Cancer Research Studies(5), Cancer-related gene regulation(4)

Publications37 total

Osteocyte-like differentiation of osteosarcoma by inorganic phosphate
Differentiation·2025· 1 cited
Inhibition of anti-apoptotic Bcl-2 family members promotes synergistic cell death with ER stress inducers by disrupting autophagy in glioblastoma
Cell Death Discovery·2025· 3 citedOpen Access
Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma
Oncogene·2024· 4 citedOpen Access
MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer
Cancer Letters·2024· 2 cited
Data from PRMT5, a Novel TRAIL Receptor-Binding Protein, Inhibits TRAIL-Induced Apoptosis via Nuclear Factor-κB Activation
2023Open Access
Data from PRMT5, a Novel TRAIL Receptor-Binding Protein, Inhibits TRAIL-Induced Apoptosis via Nuclear Factor-κB Activation
2023Open Access
Supplementary Figure S1 from PRMT5, a Novel TRAIL Receptor-Binding Protein, Inhibits TRAIL-Induced Apoptosis via Nuclear Factor-κB Activation
2023Open Access
Supplementary Figure S1 from PRMT5, a Novel TRAIL Receptor-Binding Protein, Inhibits TRAIL-Induced Apoptosis via Nuclear Factor-κB Activation
2023Open Access
Data from Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
2023Open Access
Data from Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
2023Open Access
Data from Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer
2023Open Access
Supplementary Figures S1-S7, Table S1 from Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer
2023Open Access
Supplementary Figures S1-S7, Table S1 from Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer
2023Open Access
Supplementary Figures S1-S7 from Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
2023Open Access
Supplementary Figures S1-S7 from Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
2023Open Access
Data from Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer
2023· 1 citedOpen Access
Fibroblast growth factor receptor 3 overexpression mediates <scp>ALK</scp> inhibitor resistance in <scp>ALK</scp>‐rearranged non–small cell lung cancer
Cancer Science·2022· 14 citedOpen Access
GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer
npj Precision Oncology·2022· 15 citedOpen Access
Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis
Oncogene·2021· 45 citedOpen Access
Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity
npj Precision Oncology·2021· 26 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Naoya Fujita(33), Ryohei Katayama(29), Alice T. Shaw(14), Jeffrey A. Engelman(12), Tomoko Oh‐hara(12), Luc Friboulet(11), Satoshi Takagi(11), Noriko Yanagitani(11), Makoto Nishio(11), Elizabeth L. Lockerman(10), Kengo Takeuchi(10), Yasushi Okuno(9), Justin F. Gainor(6), A. John Iafrate(6), Takashi Tsuruo(6), Hiroyuki Arai(6), Tahsin Khan(5), Makoto Taiji(5), Shigeo Sato(5), Takuya Sakashita(5)